Pozen, Teva Agree to Settlement in Treximet Patent Litigation

Pozen and Teva Pharmaceuticals USA have settled patent litigation over Teva’s ANDA for a generic version of migraine drug Treximet. Teva will be dismissed without prejudice from consolidated litigation pending in the U.S. District Court for the Eastern District of Texas against Par Pharmaceutical, Alphapharm and Dr. Reddy’s Laboratories, as well as Teva, according to Pozen.
Generic Line